Rani Therapeutics Holdings Inc (RANI) - Total Liabilities
Based on the latest financial reports, Rani Therapeutics Holdings Inc (RANI) has total liabilities worth $22.11 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rani Therapeutics Holdings Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Rani Therapeutics Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. See RANI net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Rani Therapeutics Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Rani Therapeutics Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kukdong Oil &
KO:014530
|
Korea | ₩271.00 Billion |
|
Lowell Resources Fund
AU:LRT
|
Australia | AU$2.41 Million |
|
Spirit Technology Solutions Ltd
AU:ST1
|
Australia | AU$74.11 Million |
|
AGROB Immobilien AG
F:AGR
|
Germany | €117.93 Million |
|
Everspring Industry Co Ltd
TW:2390
|
Taiwan | NT$384.61 Million |
|
SRV Group plc
HE:SRV1V
|
Finland | €377.80 Million |
|
GMM Grammy Public Company Limited
BK:GRAMMY
|
Thailand | ฿3.34 Billion |
|
Ardea Resources Ltd
AU:ARL
|
Australia | AU$28.99 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Rani Therapeutics Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RANI stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rani Therapeutics Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rani Therapeutics Holdings Inc (2019–2024)
The table below shows the annual total liabilities of Rani Therapeutics Holdings Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $33.14 Million | +2.06% |
| 2023-12-31 | $32.47 Million | -4.56% |
| 2022-12-31 | $34.02 Million | +1188.75% |
| 2021-12-31 | $2.64 Million | -98.63% |
| 2020-12-31 | $192.75 Million | +61.09% |
| 2019-12-31 | $119.66 Million | -- |
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug subst… Read more